pISSN 2636-0004
eISSN 2636-0012

Table. 2.

Adverse Events Reported in Previous Studies

Author (year) Number Ablative agent Adverse event
Rate (%) Details (n) Mild to moderate Severe
EUS-guided ethanol ablation
Gan et al11 (2005) 23 E 0 0 0
DiMaio et al12 (2011) 13 E 8 Abdominal pain (1) 1 0
Caillol et al19 (2012) 13 E 0 0 0
Park et al16 (2016) 91 E 23.1 Abdominal pain (18)
Acute pancreatitis (3)
21 0
Gómez et al15 (2016) 23 E 8.7 Acute pancreatitis (1)
Abdominal pain (1)
1 1
Choi et al28 (2019) 214 E 33.2 Abdominal pain (70)
Acute pancreatitis (21)
Duodenal stricture (2)
Bleeding (1)
Cholangitis (1)
27 3
EUS-guided ablation Including chemotherapeutic agents
Oh et al13 (2011) 52 E + P 9 Fever (1)
Acute pancreatitis (1)
Abdominal pain (1)
Pericystic spillage (1)
Splenic vein obstruction (1)
5 0
DeWitt et al14 (2014) 21 E + P 75 Abdominal pain (4)
Acute pancreatitis (3)
Peritonitis (1)
Gastric wall cyst (1)
5 4
Choi et al17 (2017) 164 E + P 9 Acute pancreatitis (6)
Pseudocyst (2)
Abscess (2)
Portal vein thrombosis (1)
Fever (1)
Splenic vein obstruction (1)
Pancreatic duct stricture (1)
Pericystic spillage (1)
Intracystic hemorrhage (1)
15 1
Kim et al23 (2017) 8 E 25 Abdominal pain (4)
Acute pancreatitis (4)
Intracystic hemorrhage (1)
5 4
28 E + P
Moyer et al25 (2017) 18 E + G + P 28 Abdominal pain (4)
Acute pancreatitis (1)
4 1
21 G + P 0 0 0

EUS, endoscopic ultrasound; E, ethanol; P, paclitaxel; G, gemcitabine.

Int J Gastrointest Interv 2022;11:119~125 https://doi.org/10.18528/ijgii220027
© Int J Gastrointest Interv